Multi-Center Real-World Outcomes of Nivolumab Plus Ipilimumab and Chemotherapy in Patients with Metastatic Non-Small-Cell Lung Cancer
暂无分享,去创建一个
A. Agbarya | A. Yakobson | F. Swaid | W. Shalata | Ahron Yehonatan Cohen | Ashraf Abu Jama | Y. Dudnik | Mohammad Sheikh Ahmad
[1] R. Dziadziuszko,et al. Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations , 2023, International journal of molecular sciences.
[2] F. Rabiee,et al. Nivolumab plus ipilimumab combination therapy in cancer: Current evidence to date. , 2023, International immunopharmacology.
[3] A. Meirovitz,et al. Long-Lasting Therapeutic Response following Treatment with Pembrolizumab in Patients with Non-Small Cell Lung Cancer: A Real-World Experience , 2023, International journal of molecular sciences.
[4] O. A. Abu Saleh,et al. A Retrospective, Single-Institution Experience of Bullous Pemphigoid as an Adverse Effect of Immune Checkpoint Inhibitors , 2022, Cancers.
[5] L. Urban,et al. Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227 , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] N. Peled,et al. Crizotinib in MET Exon 14-Mutated or MET-Amplified in Advanced Disease Non-Small Cell Lung Cancer: A Retrospective, Single Institution Experience , 2022, Oncology.
[7] N. Girard,et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. , 2022, The New England journal of medicine.
[8] Y. Guan,et al. Immune-related dissociated response as a specific atypical response pattern in solid tumors with immune checkpoint blockade , 2022, Therapeutic advances in medical oncology.
[9] A. Agbarya,et al. Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small-Cell Lung Cancer, Past, Present, and Future , 2021, Journal of clinical medicine.
[10] D. Carbone,et al. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update , 2021, ESMO open.
[11] A. Yakobson,et al. Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review , 2021, Cancers.
[12] L. Sequist,et al. Lung cancer , 2021, The Lancet.
[13] A. Porgador,et al. Rapid Response to the Combination of Lenvatinib and Pembrolizumab in Patients with Advanced Carcinomas (Lung Adenocarcinoma and Malignant Pleural Mesothelioma) , 2021, Cancers.
[14] S. Sironi,et al. Immune response evaluation criteria in solid tumors for assessment of atypical responses after immunotherapy , 2021, World journal of clinical oncology.
[15] P. Queirolo,et al. Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review , 2021, BMC cancer.
[16] I. Tai,et al. Adaptive response of resistant cancer cells to chemotherapy , 2020, Cancer biology & medicine.
[17] A. Agbarya,et al. First line Immunotherapy for Non-Small Cell Lung Cancer , 2020, Pharmaceuticals.
[18] J. Weiss,et al. Advances in the Treatment of Non-Small Cell Lung Cancer: Immunotherapy. , 2020, Clinics in chest medicine.
[19] S. Khozin,et al. Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] Yi-long Wu,et al. Emerging therapies for non-small cell lung cancer , 2019, Journal of Hematology & Oncology.
[21] J. Soria,et al. Hyperprogressive disease: recognizing a novel pattern to improve patient management , 2018, Nature Reviews Clinical Oncology.
[22] C. Presley,et al. Checkpoint Inhibitors for Non-Small Cell Lung Cancer Among Older Adults , 2017, Current Oncology Reports.
[23] I. Tabbara,et al. Immune-based Therapies for Non-small Cell Lung Cancer. , 2017, Anticancer research.
[24] M. Ahn,et al. First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study. , 2016, JAMA oncology.
[25] D. Gerber,et al. Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Haidong Dong,et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.